Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany, Samar Tharwat · 2023
Read Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study by Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany, Samar Tharwat (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10744812.txt.
Description
Mohammed Nassar and co-authors test whether a pair of ready-made antibodies can protect dialysis patients from COVID-19. Their study appeared in 2023. People on long-term dialysis respond weakly to vaccines and face high risk from the virus. The drug pair, sold as Evusheld, was approved in 2022 for prevention in high-risk groups. The team ran a blinded trial at one center with 73 patients.
Forty-three patients got a single dose of the antibodies, and thirty got a salt-water placebo. The team measured virus-blocking antibodies at the start and after one and six months. They also tracked side effects and COVID-19 cases for six months. The study asks whether borrowed antibodies can fill the gap that weak vaccine responses leave in this fragile group.
Catalog record
| CREATOR | Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany, Samar Tharwat |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |